prudence gives me confidence Dividing the current Phase 3 into the two groups is prudent and simply the right thing to do... comparing the effects of the same drug on disparate groups would have tainted the statistics... lest we forget the Billions of dollars at stake here. .. BIG pharma is most certainly doing what they can to reduce the amount of time REO and ONC are protected by patents... THIS transparency is going to be key to providing the FDA a complete above board representation of the effectiveness of REO... the weak hands ditching ONC at the moment will RUE their haste... OF course I would suspect that the shorts are taking advantage of the "sell on news" .
anyway In the scheme of things... the study continues...and the strength of the eventual results has been tempered... if you are selling into this weakness... well I am not one for calling names...
anyway... what is another 4-6 months? if it is going to mean FDA Approval? My personal timeline was somewhere near Next Spring anyway.